Parabilis Medicines, Inc. (PBLS)
Company
Parabilis Medicines, Inc. (PBLS)
Jun 10, 2026
Biotechnology
Initial Public Offering / IPOWe are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.
Chart/Sentiment
Financials
Parabilis Medicines, Inc. (PBLS)
Annual revenue is currently unavailable. More figures are available with Pro.






